Aduro BioTech, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2000-01-01
- Employees
- 251
- Market Cap
- -
- Website
- https://adurolife.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Safety of ADU-1604 in Adults With Metastatic Melanoma
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03674502
- Locations
- 🇫🇷
Hôpital de la Timone, Marseille, France
🇫🇷Hospital Saint Louis, Paris, France
🇫🇷Gustave- Roussy Institute, Villejuif, France
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03189030
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
- Conditions
- Malignant Pleural Mesothelioma
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03175172
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03122548
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-resistant Fallopian CancerPlatinum-resistant Peritoneal Cancer
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02575807
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
- Prev
- 1
- 2
- Next